'Gemcitabine' presentation slideshows

Improving Treatment and Sharing Decision Making in Pancreatic Cancer

Improving Treatment and Sharing Decision Making in Pancreatic Cancer. Activity Goals. Pancreatic Cancer: Incidence/Survival. Cellular Classification of Pancreatic Cancer. Biology of Pancreatic Cancer. Diagnosis and Staging. Endoscopic Ultrasound-guided FNA of a Pancreatic Mass Lesion.

921 views • 63 slides

New Strategies for Treatment: Pancreatic Adenocarcinoma

678 views • 44 slides

Poster Discussion

Poster Discussion. Jordan Berlin, M.D. Ingram Associate Professor, Medicine. Yes, I have a Consultant or Advisory Role to disclose. Amgen BMS Genentech Imclone Immunogen Pfizer Sanofi Yes, I have Honoraria to disclose. BMS Genentech Sanofi-Aventis. DSMB Pfizer

480 views • 29 slides

Margaret Tempero, M.D. Professor of Medicine University of California, San Francisco

Debate: This house believes that FOLFIRINOX is the best treatment for patients with metastatic pancreatic adenocarcinoma. CONTRA. Margaret Tempero, M.D. Professor of Medicine University of California, San Francisco. Turning point for clinical research in pancreatic cancer

447 views • 29 slides

310 views • 22 slides

Mace L. Rothenberg, M.D.

Developing a Patient-Tailored Strategy to Stratify and Treat Patients with Pancreatic Cancer. Mace L. Rothenberg, M.D. Professor of Medicine Ingram Professor of Cancer Research. Conflict of Interest Disclosure. Consultant or Advisory Role. Stock Ownership.

330 views • 21 slides

Discussant: M Ducreux, MD, PhD Institut Gustave Roussy, Villejuif France

TH-302 plus Gemcitabine vs. Gemcitabine in Patients with Untreated Advanced Pancreatic Adenocarcinoma. MJ Borad, Mayo Clinic, Scottsdale, AZ et al. Discussant: M Ducreux, MD, PhD Institut Gustave Roussy, Villejuif France. New drug, new concept, microenvironment.

325 views • 20 slides

PI: Lee Helman, MD Co-PI: Shreyaskumar Patel, MD

256 views • 15 slides

NSCLC Approved 1st & 2nd Line Rx

NSCLC Approved 1st & 2nd Line Rx. Vinorelbine vs 5-FU/LV. Navelbine/cisplatin. Gemcitabine/cisplatin. Paclitaxel/cisplatin. Docetaxel/cisplatin. Docetaxel - 2nd line. Summary. 4 cisplatin doublets and single agent vinorelbine approved for first-line treatment of advanced NSCLC

264 views • 8 slides

Authors: Hahn NM et al, ASCO 2009. Reviewed by: Dr. Lori Wood Abstract: 5018

A Multicentre Phase II Study of Cisplatin (C), Gemcitabine (G), and Bevacizumab (B) as First-Line Chemotherapy for Metastatic Urothelial Carcinoma (UC): Hoosier Oncology Group GU-0475. Authors: Hahn NM et al, ASCO 2009. Reviewed by: Dr. Lori Wood Abstract: 5018 Date posted: June 12, 2009.

207 views • 7 slides

Therapeutic Indication

Therapeutic Indication. Non-Small Cell Lung Cancer: Gemcitabine is indicated for the palliative treatment of adult patients with locally advanced or metastatic non?small cell lung cancer. Breast cancer :

264 views • 3 slides

Supple 1. Toxicity associated with cisplatin and gemcitabine

Supple 1. Toxicity associated with cisplatin and gemcitabine.

110 views • 1 slides